Duarte, CA, United States of America

Adrien Beau Larsen

This inventor holds 2 USPTO granted patents. Top assignee: Beckman Research Institute, City of Hope. Active years: 2022-2024.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Adrien Beau Larsen

Introduction

Adrien Beau Larsen is an accomplished inventor based in Duarte, CA. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for the TXNIP-TRX complex. With a total of 2 patents, his work is paving the way for advancements in therapeutic methods.

Latest Patents

Larsen's latest patents focus on the TXNIP-TRX complex inhibitors and methods of using the same. These patents disclose compounds and methods aimed at inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex. This innovative approach has the potential to impact various medical applications.

Career Highlights

Adrien Beau Larsen is currently affiliated with the Beckman Research Institute, City of Hope. His work at this prestigious institution has allowed him to explore groundbreaking research in the field of biochemistry. His dedication to innovation is evident in his patent filings and ongoing research.

Collaborations

Larsen has collaborated with notable colleagues such as Supriyo Bhattacharya and Nagarajan Vaidehi. These partnerships have fostered a collaborative environment that enhances the research output and innovation at the Beckman Research Institute.

Conclusion

Adrien Beau Larsen's contributions to the field of biochemistry through his patents and research at the Beckman Research Institute highlight his role as a significant inventor. His work on TXNIP-TRX complex inhibitors showcases the potential for future advancements in therapeutic methods.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…